Outlook Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

Rhea-AI Summary

Outlook Therapeutics, a late clinical-stage biopharmaceutical company, has announced that Lawrence A. Kenyon, its President, CEO, and CFO, will present at the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. During this event, Kenyon will discuss the development of ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal diseases. A video webcast of the presentation will be available on-demand starting January 11, 2021, at 6:00 AM ET on their website.

MONMOUTH JUNCTION, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will present in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.

A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com.

For more information about the event, please visit the conference website here.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:

Media Inquiries:

Harriet Ullman
Assistant Vice President
LaVoieHealthScience
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com

FAQ

What will Lawrence A. Kenyon discuss at the H.C. Wainwright BioConnect 2021 Virtual Conference?

Lawrence A. Kenyon will discuss Outlook Therapeutics' development of ONS-5010/LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal indications.

When is the H.C. Wainwright BioConnect 2021 Virtual Conference?

The H.C. Wainwright BioConnect 2021 Virtual Conference takes place from January 11 to January 14, 2021.

How can I view the presentation by Outlook Therapeutics at the conference?

A video webcast of Lawrence A. Kenyon's presentation will be available on-demand beginning January 11, 2021, at 6:00 AM ET on the Investors section of Outlook Therapeutics' website.

What is ONS-5010, and why is it significant?

ONS-5010/LYTENAVA™ is significant as it aims to be the first FDA-approved ophthalmic formulation of bevacizumab-vikg for treating retinal diseases like wet AMD.

What are the potential markets for ONS-5010 if approved?

If approved, ONS-5010 could be commercialized in the United States, United Kingdom, Europe, Japan, China, and other markets.